Tagista, pills 16mg, 30pcs

Composition

1 tablet contains

Active ingredient:  

Betahistine dihydrochloride 8.0 mg; 16.0 mg; 24.0 mg;

Auxiliary substances:  

Microcrystalline cellulose- 54,75/109,5/164,25 mg,

Povidone (collidone 25)— 9,0/18,0/27,0 mg

Potato starch— 20,0/40,0/60,0 mg,

Citric acid— 2,0/4,0/6,0 mg,

Colloidal silicon dioxide (aerosil), — 3,0/6,0/9,0 mg,

Talcum powder— 2,8/5,6/8,4 mg,

Magnesium Stearate— 0,45/0,9/1,35 mg

Pharmacological action

Betahistine acts mainly on histamine H1 and H3 receptors of the inner ear and vestibular nuclei of the central nervous system. By direct agonistic action on the H1-receptors of the inner ear vessels, as well as indirectly through the action on the NC-receptors, it improves microcirculation and capillary permeability, normalizes endolymph pressure in the labyrinth and cochlea. At the same time, betahistine increases blood flow in the basilar artery. It has a pronounced central effect, being an inhibitor of NC receptors of the vestibular nerve nuclei. Normalizes conduction in neurons of the vestibular nuclei at the level of the brain stem. The clinical manifestation of these properties is a decrease in the frequency and intensity of dizziness, a decrease in tinnitus, and an improvement in hearing in the case of its decrease. Pharmacokinetics are rapidly absorbed and plasma protein binding is low. The time to reach the maximum concentration in blood plasma is 3 hours. It is almost completely excreted by the kidneys as a metabolite (2-pyridylacetic acid) within 24 hours. The elimination half-life is 3-4 hours.

Indications

• Treatment and prevention of vestibular vertigo of various origins;
• Syndromes that include dizziness and headache, tinnitus, progressive hearing loss, nausea, and vomiting.
• Meniere’s disease or syndrome.

Contraindications

• Hypersensitivity to any of the components of the drug;
• age under 18 years (due to lack of data);
• pregnancy and lactation (due to lack of data).

With caution Ulcer of the stomach or duodenum 12 (including in the anamnesis), pheochromocytoma, bronchial asthma. These patients should be monitored regularly during treatment.

Side effects

Gastrointestinal disorders. the appearance of hypersensitivity reactions from the skin (rash, itching, urticaria), angioedema.

Interaction

Interactions or incompatibilities with other medicinal products are unknown.

How to take, course of use and dosage

Inside, while eating. Tablets 16 mg: 1/2-1 tablet 3 times a day. Improvement is usually noted already at the beginning of therapy, a stable therapeutic effect occurs after two weeks of treatment and can increase over several months of treatment. Long-term treatment. The duration of treatment is determined individually.

Overdose

Symptoms:  nausea, vomiting, convulsions.

Treatment:  gastric lavage, taking activated charcoal, symptomatic therapy.

Special instructions

Effects on the ability to drive vehicles and work with mechanicsmibetahistine does not have a sedative effect and does not affect the ability to drive a car or engage in activities that require rapid psychomotor reactions.

Form of production

Tablets

Storage conditions

In a dry place, protected from light, at a temperature not exceeding 25°C. Keep out of reach of children.

Shelf life

3 years

Active ingredient

Betahistine

Conditions of release from pharmacies

By prescription

Dosage form

Tablets

Description

For adults as directed by your doctor

Indications

Cerebrovascular accident, Meniere ‘s Disease